Equities analysts predict that Dermira Inc (NASDAQ:DERM) will report $34.16 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Dermira’s earnings, with the highest sales estimate coming in at $34.60 million and the lowest estimate coming in at $33.37 million. Dermira posted sales of $39.08 million during the same quarter last year, which suggests a negative year over year growth rate of 12.6%. The business is expected to report its next quarterly earnings results on Monday, August 5th.
According to Zacks, analysts expect that Dermira will report full-year sales of $67.97 million for the current fiscal year, with estimates ranging from $49.60 million to $103.72 million. For the next year, analysts expect that the firm will post sales of $64.97 million, with estimates ranging from $43.70 million to $101.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Dermira.
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.39). The company had revenue of $2.45 million during the quarter, compared to analysts’ expectations of $2.63 million. Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%.
In other news, insider Eugene A. Bauer sold 35,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.00, for a total transaction of $525,000.00. Following the completion of the transaction, the insider now directly owns 43,900 shares in the company, valued at approximately $658,500. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 14.80% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp purchased a new position in shares of Dermira during the 1st quarter valued at approximately $44,000. Advisor Group Inc. boosted its stake in shares of Dermira by 117.0% during the 1st quarter. Advisor Group Inc. now owns 6,062 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 3,269 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Dermira by 32.0% during the 1st quarter. HighTower Advisors LLC now owns 17,244 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 4,181 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Dermira by 1.6% during the 1st quarter. Northern Trust Corp now owns 439,374 shares of the biopharmaceutical company’s stock valued at $5,954,000 after buying an additional 7,103 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Dermira by 48,273.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 7,241 shares during the last quarter. Institutional investors own 83.38% of the company’s stock.
NASDAQ DERM traded down $0.23 on Thursday, reaching $9.72. The company had a trading volume of 688,289 shares, compared to its average volume of 1,620,368. The stock has a market cap of $522.21 million, a PE ratio of -1.85 and a beta of 1.32. Dermira has a 1 year low of $6.00 and a 1 year high of $15.48. The company has a quick ratio of 6.92, a current ratio of 7.13 and a debt-to-equity ratio of 4.36.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Read More: What is a resistance level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.